Matthew Li

Director, Cell Therapy CMC • Tome Biosciences

Matthew Li is Biomedical Scientist and Engineer with over 14 years of experience across an array of areas in the academic and industrial biotech field including CGT R&D and manufacturing, translational medical device development, and clinical research. He is currently a Director at Tome Biosciences driving cell therapy CMC strategies. He has held roles at Vor Biopharma and Takeda engaging across the CGT value chain interfacing with research, development, manufacturing, quality, regulatory, clinical, business development, and commercial taking an integrative approach to address challenges across the life cycle of a therapy. Matthew holds a PhD in Medical Engineering and Medical Physics from the joint Health Sciences and Technology program of Massachusetts Institute of Technology and Harvard Medical School.

Also Speaking

Lara Silverman

Founder • LIS BioConsulting

Anthony Davies

Founder & Chief Executive Officer • Dark Horse Consulting

James Kusena

Vice President, Bioprocessing & Applications • MicrofluidX

Event Info


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.